PERSONAL INFORMATION

Alessandro Natoni

UniCamillus-Saint Camillus International University of Health Sciences,
8, di Sant'Alessandro street - 00131 Rome, Italy

alessandro.natoni@unicamillus.org; alessandronatoni@pec.it

https://orcid.org/0000-0003-4321-9005; linkedin.com/in/alessandro-natoni-57ab3b61

Sex M | Date of birth 04/10/1974 | Nationality Italian

WORK EXPERIENCE

From 27/07/2026 - Present

Associate Professor in the scientific disciplinary field of "Malattie del sangue", GSD "06/MEDS-09 Malattie del sangue, Oncologia e Reumatologia", SSD "MEDS-09/B Malattie del sangue", Bachelor Degree in Medicine and Surgery (LM-41)

UniCamillus-Saint Camillus International University of Health Sciences, 8 Sant'Alessandro street - 00131 Rome, Italy

From 02/09/2024 to 24/07/2026

RTDA (Senior Researcher type A)

Sapienza University, Department of Translational e Precision Medicine, Policlinico Umberto I, Hematology Section, Rome, Italy

Project title: The role of sialylation in haematological malignancy dissemination and immune evasion

From 01/03/2020 to 01/09/2024

iCARE-2 Principal Investigator

Sapienza University, Department of Translational e Precision Medicine, Policlinico Umberto I, Hematology Section, Rome, Italy

Project title: The role of sialofucosylated structures in Multiple Myeloma progression and immune evasion

From 01/10/2019 to 28/02/2021

Adjunct Professor in Genetics and Principles of Genetic Engineering (BIO/18), Bachelor's Degree in Biotechnology, academic year 2019/2020

Department of "Innovazione nei Sistemi Biologici, Agroalimentari e Forestali", University of Tuscia, Viterbo, Italy

From 01/02/2012 to 01/06/2019

Senior researcher

National University of Ireland Galway, School of Medicine, Galway, Ireland

Project title: Explore the role of E-Selectin/E-Selectin ligand interactions in Multiple Myeloma and its clinical application

From 01/10/2009 to 01/02/2012

Postdoctoral researcher

National University of Ireland Galway, National Centre for Biomedical Engineering Science, Galway, Ireland

Project title: Investigating the efficacy of a novel Cdc7/CDK9 kinase inhibitor in Chronic Lymphocytic Leukemia

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

From 07/08/2007 to 30/09/2009

Postdoctoral researcher

National University of Ireland Galway, Department of Biochemistry, Galway, Ireland

Project title: Define novel therapeutic strategies to overcome Tumor necrosis factor-Related Apoptotic Inducing Ligand (TRAIL) resistance in cancer cells

From 22/11/2005 to 17/11/2006

Postdoctoral researcher

Medical Research Council, University of Leicester, Toxicology Unit, Leicester, UK

Project title: Apoptotic-inducing activity of a novel monoclonal agonistic antibody against Death Receptor 5 in combination with a new Histone Deacetylase Inhibitor (HDACi) in Chronic Lymphocytic Leukemia

EDUCATION AND TRAINING

18/12/2023

National scientific qualification (ASN) as Associate Professor in the Italian higher education system for the disciplinary fields of

- 06/D3 Malattie del Sangue, Oncologia e Reumatologia;
- 06/A2 Patologia Generale e Patologia Clinica;
- 06/N1 Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate.

15/09/2006

Ph.D. in Biomedical and Life Sciences

University of Surrey, faculty of Health and Medical Sciences, Guildford, UK

Thesis on “Molecular mechanisms of Feline Calicivirus-induced apoptosis”. Supervisors: Dr Lisa O. Roberts and Dr George E.N. Kass.

2001

Qualification to practice as a biologist

Awarded by the University of Tuscia, Viterbo, Italy. Registered with the national professional body “Ordine Nazionale dei Biologi” since 21/09/2021.

18/07/2001

Master’s degree in Biological Sciences (summa cum laude)

University of Tuscia, Viterbo, Italy

Experimental Thesis on “Factors modulating the genetic instability induced by Epstein-Barr virus in B lymphoma cells” (Italian language). Supervisor: Prof. Giampiero Gualandi.

1993

High school diploma (Maturità Classica)

Liceo Classico “Mariano Buratti”, Viterbo, Italy

TEACHING EXPERIENCE

- Academic year 2025/2026. Lecturer in “Metodologia Clinica: semeiotica medica e interazione bioelettromagnetica – anamnesi, esame obiettivo, ragionamento clinico, medicina narrativa, problem solving”, Sapienza University, Department of Translational e Precision Medicine, Policlinico Umberto I, Rome, Italy. Second year students in Medicine and Surgery, HT LM-41R (4 cfu), total hours 50
- Academic year 2025/2026. Lecturer in “Approccio alle metodologie e tecnologie innovative in medicina interna, tecniche di BSL”, Sapienza University, Department of Translational e Precision Medicine, Policlinico Umberto I, Rome, Italy. Second year students in Medicine and Surgery, HT LM-41R (4 cfu), total hours 50
- Academic year 2019/2020. Adjunct Professor in Genetics and Principles of Genetic Engineering (BIO/18), Department of “Innovazione nei Sistemi Biologici, Agroalimentari

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

e Forestali", University of Tuscia, Viterbo, Italy. Bachelor's Degree in Biotechnology, L-2 (9 CFU), total hours 72

- Academic year 2016/2017 and 2017/2018. Delivered "Protein Homeostasis" lecture in the "MSc programme in Cancer Research", National University of Ireland Galway, Galway, Ireland
- Academic year 2016/2017 and 2017/2018. Delivered "General Aspects of Haematological Malignancies" lecture in the "MSc programme in Cancer Research", National University of Ireland Galway, Galway, Ireland
- Academic Year 2016/2017 and 2017/2018. Delivered "Cancer Chemotherapy" module to the 2nd year Medical Students, National University of Ireland Galway, Galway, Ireland.
- Academic year 2017/2018. Delivered "Aseptic Technique for Tissue Culture Laboratory" practical module for the Cellular Manufacturing and Therapy MSc course, National University of Ireland Galway, Galway, Ireland
- 31/05/2017. Delivered the practical workshop "Myeloma processing workshop" on the isolation of CD138 positive myeloma cells from the bone marrow samples derived from multiple myeloma patients. National University of Ireland Galway, Galway, Ireland
- Academic year 2003/2004 and 2004/2005, demonstrator for the "Medical Microbiology" MSc course in the School of Biomedical and Molecular Sciences, University of Surrey, Guildford UK
- Academic year 2004/2005, demonstrator for the "Animal and Plant Virology" course and the Medical Microbiology MSc course in the School of Biomedical and Molecular Sciences, University of Surrey, Guildford UK

HONOURS AND AWARDS

- iCARE-2 2019 Fellowship Co-funded by Fondazione AIRC and the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 800924. Awarded on the 5th of November 2019
- Hematology Association of Ireland Educational Bursary, Special Merit. Awarded on the 17th of October 2015
- University Research Scholarship for a research degree (PhD) in the School of Biomedical and Life Sciences, University of Surrey, Guildford, UK. Awarded on the 1st of October 2002.

COURSES

- Multicolor Panel Design and FlowJo (Policlinico Univ. Agostino Gemelli, 22/02/2023)
- Nature Masterclass in Scientific Writing and Publishing certificate (National University of Ireland, 2017)
- Chemical and biological safety in the laboratory for users and managers training (National University of Ireland Galway, 2017)
- Compressed gas safety training, including cryogenics gas (National University of Ireland Galway, 2017)
- Workplace posture and manual handling training (National University of Ireland Galway, 2017)
- Second International IMF-Euro Flow Workshop in Myeloma Minimal Residual Disease (Salamanca, Spain, 2016)
- Selecting and awarding quotation & mini-tender competitions training (National University of Ireland Galway, 2016)
- Record of training handling and transportation of dangerous goods training (Mayo Medical Laboratories, 2011)
- Commercialization and Enterprise certificate (University of Surrey, UK, 2005).

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

CERTIFICATIONS

- Office Skills Diploma (Excel, Word, PowerPoint, Access) awarded by the Pitman Training Galway on the 3rd of May 2019. Level achieved: distinction
- Cambridge English: Proficiency (CPE) C2 level awarded on the 23rd of January 2019 and released by Cambridge English Language Assessment, Cambridge, UK
- Photoshop and Illustrator CC certificate awarded by the Pitman Training Galway on 27th of April 2018. Level achieved: distinction
- Selecting & Awarding Quotation and Mini-tender Competitions certificate awarder on the 18th of May 2016 by the Procurements & Contracts Office, National University of Ireland Galway, Galway, Ireland
- Cambridge English: Advanced (CAE) C1 level awarded on the 3rd of October 2016 and released by Cambridge English Language Assessment, Cambridge, UK
- Last Ireland and UTG UK certificate for carrying out experimental and other scientific procedures on living animals awarded on the 28th of June 2012
- Animals (Scientific Procedures) Act 1986, University Training Group for carrying out experimental and other scientific procedures on living animals awarded on 18th of July 2012 and released by Home Office, London, UK.

INVITED SPEAKER

- 2019, 31st January. Targeting sialylation within the tumor microenvironment in multiple myeloma. Advance theranostic nanomedicine in oncology. ERC starting grant SLaMM workshop, Pontedera, Pisa, Italy.

ORAL PRESENTATION

- 2018, 22nd February. Flow Cytometry Symposium, National University of Ireland Galway, Galway, Ireland. “Role of platelets/myeloma interactions in malignant cells dissemination and metastasis”
- 2017, 31st May. Myeloma processing Workshop, National University of Ireland Galway, Galway, Ireland "MM sample processing procedure", "Immunophenotyping of MM with flow cytometry", "Isolation of CD138 positive myeloma cells”
- 2015, 16-17 October. Haematology Association of Ireland, Galway, Ireland. “E-selectin ligand expression increases with progression of myeloma and induces drug resistance in a murine transplant model, which is overcome by the glycomimetic E-selectin antagonist, GMI1271”
- 2014, 16th December. Flow Cytometry Research Day, National University of Ireland Galway, Galway, Ireland. “Phenotypic characterization of a sub-population of multiple myeloma”
- 2010, 14-16 October. Haematology Association of Ireland, Galway, Ireland. “A dual Cdc7/CDK9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells”
- 2009, 15-17 October. Haematology Association of Ireland, Kilkenny, Ireland. “Apoptotic-inducing activity of PHA-767491, a new Cdc7/CDK9 inhibitor, in primary Chronic Lymphoid Leukemia cells”
- 2005, 1st July. 2nd annual Festival of Research, University of Surrey, Guildford, UK. “The activation of caspase 9 precedes mitochondrial Bax translocation and cytochrome c release in Feline Calicivirus-induced apoptosis”
- 2005, 4-7 April. Society for General Microbiology 156th meeting, Heriot-Watt University, Edinburgh, Scotland. “The activation of caspase 9 precedes mitochondrial Bax translocation and cytochrome c release in Feline Calicivirus-induced apoptosis”
- 2004, 6-10 November. 2nd International Calicivirus Conference, Dijon, France. “Feline Calicivirus-induced apoptosis occurs through the mitochondrial pathway”
- 2001, 10-11 May. ABCD Meeting “Stress Cellulare”, Università Tor Vergata, Roma, Italia. “Oxidative stress induced by Epstein-Barr virus in B lymphoma cells”.

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

PATENT

- "Treatment of proliferative disorders with death receptors agonist", Publication Number: US 20110262455 A1, EP2352504A2, WO2010041140A2, WO2010041140A3 (2011).

MEMBERSHIPS

- Referee for the scientific journals "Toxicology and Applied Pharmacology" and "Journal of Cellular and Molecular Medicine".

LANGUAGE SKILLS

Mother tongue: Italian

Other language	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

Certificate "Cambridge English: Proficiency" (CPE) C2 level awarded on 23-01-2019 and released by Cambridge English Language Assessment, Cambridge, UK

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
Common European Framework of Reference for Languages

DIGITAL SKILLS

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Proficient user	Proficient user	Proficient user	Proficient user	Proficient user

Levels: Basic user - Independent user - Proficient user
Digital competences - Self-assessment grid

Microsoft Office Diploma (PowerPoint, Access, Word expert and Excel expert), certificate in Adobe Illustrator and Photoshop

- Proficient in flow cytometry software packages in clinical and research setting including, Infinicyt, Flow Jo and FACSCanto Diva
- Expert in Microsoft Office Word, Excel, PowerPoint and Access
- Basic knowledge of image editing software such as Adobe Photoshop, Illustrator and Image-Pro Premier

SCIENTIFIC PUBBLICATIONS

Articles in a journal

1. O'Dwyer M, Kirkham-McCarthy L, Cerreto M, Foà R, **Natoni A**. (2024). PSGL-1 decorated with sialyl Lewis$^{a/x}$ promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement. Sci Rep 19;14(1): 1756.doi: 10.1038/s41598-024-52212-2
2. **Natoni A**, Cerreto M, De Propris MP, Petrucci MT, Fazio F, Intoppa S, Milani ML, Kirkham-McCarthy L, Henderson R, Swan D, Guarini A, O'Dwyer M, Foà R. (2023) Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity. Cancers (Basel) 5;15(7):2154. doi: 10.3390/cancers15072154.
3. **Natoni A**, Cerreto M, De Propris MS, Del Giudice I, Soscia R, Peragine N, Intoppa S, Milani ML, Guarini A, Foà R. (2023). Sialylation regulates migration in chronic lymphocytic leukemia. Haematologica. 1;108(7):1851-1860. doi:

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

10.3324/haematol.2022.281999.

4. Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, **Natoni A**, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. (2022). CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 22(11): 847-852 doi: 10.1016/j.clml.2022.07.011.
5. Burke AJ, McAuliffe JD, **Natoni A**, Ridge S, Sullivan FJ, Glynn SA. (2022). Chronic nitric oxide exposure induces prostate cell carcinogenesis, involving genetic instability and a pro-tumorigenic secretory phenotype. Nitric Oxide 127:44-53. doi: 10.1016/j.niox.2022.07.005.
6. Daly J, Sarkar S, **Natoni A**, Stark JC, Riley NM, Bertozzi CR, Carlsten M, O'Dwyer M. (2022). Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses. Blood Adv 6(11):3352-3366. doi: 10.1182/bloodadvances.2021006805.
7. Soh KT, Came N, Otteson GE, Jevremovic D, Shi M, Olteanu H, **Natoni A**, Lagoo A, Theakston E, Óskarsson JÞ, Gorniak M, Grigoriadis G, Arroz M, Fletcher M, Lin P, Ludwig P, Tembhare P, Matuzeviciene R, Radzevicius M, Kay S, Chen W, Cabrita C, Wallace PK. (2022). Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. Cytometry B Clin Cytom 102(2):88-106. doi: 10.1002/cyto.b.22053.
8. Naicker SD, Feerick CL, Lynch K, Swan D, McEllistrim C, Henderson R, Leonard NA, Treacy O, **Natoni A**, Rigalou A, Cabral J, Chiu C, Sasser K, Ritter T, O'Dwyer M, Ryan AE. (2021). Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology 10(1):1859263. doi:10.1080/2162402X.2020.1859263.
9. Sarkar S, Chauhan SKS, Daly J, **Natoni A**, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M. (2020). The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. Cancer Immunol Immunother 69(3):421-434. doi: 10.1007/s00262-019-02477-8.
10. Swan D, Delaney C, **Natoni A**, O'Dwyer M, Krawczyk J. (2020). Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). Haematologica 105(3):e141-e143. doi: 10.3324/haematol.2019.228338.
11. **Natoni A**, Farrell ML, Harris S, Falank C, Kirkham-McCarthy L, Macauley MS, Reagan MR, O' Dwyer M. (2020) Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model. Haematologica. doi: 10.3324/haematol.2018.212266.
12. O'Dwyer M, Henderson R, Naicker SD, Cahill MR, Murphy P, Mykytiv V, Quinn J, McEllistrim C, Krawczyk J, Walsh J, Lenihan E, Kenny T, Hernando A, Hirakata G, Parker I, Kinsella E, Gannon G, **Natoni A**, Lynch K and Ryan AE. (2019) CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 25; 3(12):1815-1825 doi: doi: 10.1182/bloodadvances.2019000010.
13. **Natoni A**., Smith T. A. G., Keane N., McEllistrim C., Connolly C., Jha A., Andrulis M., Ellert E., Raab M.S., Glavey S.V., Kirkham-McCarthy L., Kumar S.K., Locatelli-Hoops S.C., Oliva I., Fogler W.E., Magnani J.L. and O'Dwyer M. (2017) E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. Leukemia 12: 2642-2651. doi: 10.1038/leu.2017.123
14. Glavey S.V., Manier S., **Natoni A**., Sacco A., Moschetta M., Reagan M.R., Murillo L.S., Sahin I., Wu P., Mishima Y., Zhang Y., Zhang W.J., Zhang Y., Morgan G., Joshi L., Roccaro A.M., Ghobrial I.M. and O'Dwyer, M. E. (2014) The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood 124, 1765-1776. doi: 10.1182/blood-2014-03-560862

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

15. FitzGerald J., Murillo L.S., O'Brien G., O'Connell E., O'Connor A., Wu K., Wang G. N., Rainey M.D., **Natoni A**., Healy S., O'Dwyer M. and Santocanale C. (2014) A high through-put screen for small molecules modulating MCM2 phosphorylation identifies ryuvidine as an inducer of the DNA damage response. Plos One 9 (6): 1-11. doi: 10.1371/journal.pone.0098891
16. **Natoni A**., Coyne M.R., Jacobsen A., Rainey M.D., O'Brien G., Healy S., Montagnoli A., Moll J., O'Dwyer, M. and Santocanale C. (2013) Characterization of a dual CDC7/CDK9 Inhibitor in multiple myeloma cellular models. Cancers (Basel) 5, 901-918. doi: 10.3390/cancers5030901
17. Gupta S., Giricz Z., **Natoni A**., Donnelly N., Deegan S., Szegezdi E. and Samali, A. (2012) NOXA contributes to the sensitivity of PERK-deficient cells to ER stress. Febs Lett 586, 4023-4030. doi: 10.1016/j.febslet.2012.10.002
18. Szegezdi, E., Reis, C. R., van der Sloot, A. M., **Natoni, A**., O'Reilly, A., Reeve, J., Cool, R. H., O'Dwyer, M., Knapper, S., Serrano, L., Quax, W. J., and Samali, A. (2011) Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med 15, 2216-2231. doi: 10.1111/j.1582-4934.2010.01211.x
19. **Natoni A**., Murillo L.S., Kliszczak A.E., Catherwood M.A., Montagnoli A., Samali A., O'Dwyer M. and Santocanale C. (2011) Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther 10, 1624-1634. doi: 10.1158/1535-7163.MCT-10-1119
20. Napolitano C., **Natoni A**., Santocanale C., Evensen L., Lorens J.B. and Murphy P. V. (2011) Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorg Med Chem Lett 21, 1167-1170. doi: 10.1016/j.bmcl.2010.12.100
21. Reis C.R., van der Sloot A.M., **Natoni A**., Szegezdi E., Setroikromo R., Meijer M., Sjollema K., Stricher F., Cool R.H., Samali A., Serrano L. and Quax, W. J. (2010) Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis 1:e83. doi: 10.1038/cddis.2010.61
22. Mahalingam D., **Natoni A**., Keane M., Samali A. and Szegezdi E. (2010) Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Brit J Cancer 102, 754-764. doi: 10.1038/sj.bjc.6605545
23. Reis C.R., van der Sloot A M., Szegezdi E., **Natoni A**., Tur V., Cool R.H., Samali A., Serrano L. and Quax, W. J. (2009) Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry-Us 48, 2180-2191. doi: 10.1021/bi801927x
24. **Natoni A**., MacFarlane M., Inoue S., Walewska R., Majid A., Knee D., Stover D.R., Dyer M.J.S. and Cohen, G. M. (2007) TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Brit J Haematol 139, 568-577. doi: 10.1111/j.1365-2141.2007.06852.x
25. Belfiore M.C., **Natoni A**., Barzellotti R., Merendino N., Pessina G., Ghibelli L., and Gualandi, G. (2007) Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells. Cancer Lett 254, 236-243. doi: 10.1016/j.canlet.2007.03.010
26. **Natoni A**., Kass G.E.N., Carter M.J. and Roberts, L. O. (2006) The mitochondrial pathway of apoptosis is triggered during feline calicivirus infection. J Gen Virol 87, 357-361. doi: 10.1099/vir.0.81399-0
27. Goodfellow I., Chaudhry Y., Gioldasi I., Gerondopoulos A., **Natoni A**., Labrie L., Laliberte J. F. and Roberts, L. (2005) Calicivirus translation initiation requires an interaction between VPg and eIF4E. Embo Rep 6, 968-97. doi: 10.1038/sj.embor.7400510

Reviews

1. Cerreto M, Foà R, Natoni A. (2023). The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia. Cancers (Basel) 26;15(21):5160. doi: 10.3390/cancers15215160
2. **Natoni A**, Bohara R, Pandit A, O'Dwyer M. (2020). Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment. Front Bioeng Biotechnol 7:252. doi: 10.3389/fbioe.2019.00252.

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

3. **Natoni A**., Macauley M. S., and O'Dwyer M. E. (2016) Targeting selectins and their ligands in cancer. Front Oncol 6:93. doi: 10.3389/fonc.2016.00093
4. Keane N. A., Reidy M., **Natoni A**., Raab M. S., and O'Dwyer M. (2015) Targeting the Pim kinases in multiple myeloma. Blood Cancer J 5:e325. doi: 10.1038/bcj.2015.46

Book Chapter

1. **Natoni A**., O'Dwyer M. and Santocanale C. (2013) A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization. Methods Mol Biol 986, 217-226. doi: 10.1007/978-1-62703-311-4_14

Meeting Abstracts

1. **A. Natoni**, M. Cerreto, M. S. De Propris, M. T. Petrucci, I. Del Giudice, S. Intoppa, M. L. Milani, L. Kirkham-McCarthy, R. Henderson, D. Swan, M. O'Dwyer, A. Guarini, R. Foà (2022). Sialofucosylated structures enable platelet binding to myeloma cells conferring protection from NK-mediated cytotoxicity. HemaSphere 6: p861
2. Swan, D; O'Dwyer, ME; Cahill, M; Krawczyk, J; Mykytiv, V; Quinn, J; Henderson, R; McEllistrim, C; Hernando, A; Parker, I; Nolan, M; Lenihan, E; Szegezdi, E; Naicker, SD; Lynch, K; **Natoni, A**; Ryan, A; Murphy, P (2021). Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Blood 138 (1)
3. Daly, J; Sarkar, S; **Natoni, A**; Henderson, R; Swan, D; Carlsten, M; O'Dwyer, ME (2019). Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor. Blood 134 (1): 138
4. Daly, J; Sarkar, S; **Natoni, A**; Henderson, R; Swan, D; Carlsten, M; O'Dwyer, ME (2019). Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor. Clinical Lymphoma Myeloma & Leukemia 19 (10): FP-181
5. Henderson R., Kirkham-McCarthy L., Dawn Swan D., O'Dwyer M. and **Natoni A**. (2018) Platelets preferentially bind to myeloma cells bearing sialofucosylated structures and protect them from natural killer cell-mediated cytotoxicity. Blood 132 (1): 4453
6. **Natoni A**., Farrell M., Fairfield H., Kirkham-McCarthy L., Macauley M., Reagan M. and O'Dwyer M. (2018) Inhibition of sialylation impairs adhesion on MadCAM-1 and E-selectin and sensitize multiple myeloma cells to bortezomib in a xenograft mouse model. Blood 132 (1): 3204
7. Sarkar S., Chauhan S., Stikvoort A., **Natoni A**., Daly J., Henderson R., Mutis T. and O'Dwyer M. (2018) $CD38^{low}$ natural killer cells transiently expressing CD16 (f158v) mRNA potentiates the therapeutic activity of Daratumumab against multiple myeloma with minimal effector NK cell fratricide. Blood 132 (1): 3199
8. Henderson R., Cahill M.R., Murphy P., Mykytiv V., Quinn J., Walsh J., Lenihan E., Kenny T., Hernando A., Hirakata G., Parker I., Kinsella E., Gannon G., **Natoni A**. and Michael E O'Dwyer. (2018) Cybord-Dara is a highly effective upfront treatment for newly diagnosed multiple myeloma. Initial efficacy results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 study. Blood 132 (1): 3242
9. Sarkar S., Chauhan S., **Natoni A**., Daly J., Henderson R. and O'Dwyer M. (2018) Engineering CD38 low natural killer cells to transiently express CD16 (f158v) mRNA enhances the cytotoxic potential of Daratumumab against multiple myeloma with minimal NK cell fratricide. Human Gene Therapy 29 (11): A8
10. Reagan M., Farrell M., Macauley M., **Natoni A**., Fairfield H. and Michael O'Dwyer. (2018) Combination targeting of sialylation and the proteasome inhibits tumor growth and increases survival in a humanized mouse multiple myeloma model. EHA Learning Center. 214984
11. Daly J., Sarkar S., **Natoni A**., Hu J., Chauhan S., Henderson R., Duggan T., Kirkham L., McEllistrim C. and Michael O'Dwyer. (2018) Targeting siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer

© European Union, 2002-2017 | europass.cedefop.europa.eu

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

cells against multiple myeloma. EHA Learning Center. 216407

12. Keane N., **Natoni A**., Sharik M., Chesi M., Bergsagel P. L. and O'Dwyer, M. (2018) Novel kinase inhibitors afuresertib and PIM447 are active alone and in combination with standard therapies, respectively, in a predictive MM in vivo model, and a crispr genome-wide screening approach identifies clinically-relevant biomarkers determining susceptibility to these therapeutic strategies. Haematologica 103, 9-10
13. Naicker S., Rigalou A., McEllistrim C., Henderson R., **Natoni A**., Chiu C., Sasser K., Ryan A. and O'Dwyer, M. (2018) Low dose cyclophosphamide potentiates the anti-myeloma activity of Daratumumab through augmentation of macrophage-induced ADCP. Haematologica 103, 16-17
14. Daly J., Sarkar S., **Natoni A**., Hu J., Chauhan S., Henderson R., Duggan T., McCarthy P. L., McEllistrim C. and O'Dwyer, M. (2018) Targeting siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer cells against multiple myeloma. Haematologica 103, 17
15. Daly J., Duggan T., Hu J.S., **Natoni A**., Sarkar S., Kirkham-McCarthy L., McEllistrim, C., Krawczyk, J. and O'Dwyer, M. (2017) Targeting Siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer cells against multiple myeloma. Blood 130 (1): 1799
16. Naicker S., Rigalou, A., McEllistrim C., **Natoni A**., Chiu C., Sasser K., Ryan A. and O'Dwyer M. (2017) patient data supports the rationale of low dose cyclophosphamide to potentiate the anti-myeloma activity of Daratumumab through augmentation of macrophage-induced ADCP. Blood 130 (1): 121
17. Rigalou A., Ryan A., **Natoni A**., Chiu C., Sasser K., and O'Dwyer M. E. (2016) potentiation of anti-myeloma activity of Daratumumab with combination of cyclophosphamide, lenalidomide or bortezomib via a tumor secretory response that greatly augments macrophage-induced ADCP. Blood 128 (22): 2101
18. Connolly C., Jha A., **Natoni A**. and O'Dwyer M. (2016) A 13-glycosylation gene signature in multiple myeloma can predicts survival and identifies candidates for targeted therapy (GiMM13). Blood 128 (22):4423
19. **Natoni A**., Smith T. A. G., Keane N., Locatelli-Hoops S. C., Oliva I., Fogler W.E., Magnani J.L. and O'Dwyer M. (2015) E-selectin ligand expression increases with progression of myeloma and induces drug resistance in a murine transplant model, which is overcome by the glycomimetic e-selectin antagonist, GMI-1271. Blood 126 (23): 1805
20. Keane N., Reidy M., **Natoni A**. and O'Dwyer M. (2015) Concurrent inhibition of Pim and Akt pathways with PIM447 and afuresertib activates FOXO3a and depletes c-myc to induce synergistic cell death in multiple myeloma. Blood 126 (23): 3007
21. **Natoni A**., Moschetta M., Glavey S., Wu P., Morgan G.J., Joshi L., Magnani J.L., Ghobrial I.M. and O'Dwyer, M. E. (2014) Multiple myeloma cells express functional E-selectin ligands which can be inhibited both in-vitro and in-vivo leading to prolongation of survival in a murine transplant model. Blood 124 (21): 4718
22. Glavey S., Manier S., Sacc, A., Reagan M.R., Mishima Y., Zhang Y., Sahin I., Zhang Y., Zhang W.J., Murillo L.S., Loughrey C., **Natoni A**., Kazlowska K., Joshi L., Roccaro A.M., Ghobrial I.M. and O'Dwyer, M. (2013) Silencing the sialyltransferase gene ST3GAL6 inhibits adhesion and migration of myeloma cells in vitro and reduces the homing and proliferation of tumor cells in vivo. Blood 122 (21): 275
23. Reis C.R., van der Sloot A.M., Szegezdi E., **Natoni A**., Tur V., Cool R.H., Samali A., Serrano L. and Quax, W. J. (2011) Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Adv Exp Med Biol 691, 807-808
24. Szegezdi E, van der Sloot A.M., **Natoni A**., Mahalingam D., Cool R.H., Munoz I.G., Montoya G., Quax W. J., de Jong Luis Serrano S. and Samali A. (2011) Improved tumor cell killing by TRAIL requires selective and high affinity receptor activation. Adv Exp Med Biol 691, 808
25. Quax W.J., Reis C.R., van der Sloot A.M., Tur V., Szegezdi E., **Natoni A**., Cool R.H.,

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document

Samali A. and Serrano, L. (2011) Designed receptor specific rhTRAIL variants enhance induction of apoptosis in cancer cells. Adv Exp Med Biol 691, 726-727

26. Santocanale A., **Natoni A**., Murillo L., Catherwood M., Montagnoli A., Samali A. and O'Dwyer, M. (2010) Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells. Ejc Suppl 8, 161
27. **Natoni A**., Hayat A., Montagnoli A., Callagy G., Samali A., Santocanale C. and O'Dwyer, M. C. (2009) PHA767491, a Dual Cdc7/CDK9 inhibitor, with potential to target both proliferation and survival in CLL. Blood 114 (22): 2366

BIBLIOMETRIC INDICATORS

- Hirsch index: 20 (data base Scopus)
- Total citations (without self-citations): 1225 (data base Scopus)
- Average Citations per Item: 36 (data base Scopus).

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal data contained in this document